Information on this company is supplied by EMIS which is part of Euromoney Institutional Investor plc, one of Europe's largest publishers and a constituent of the FTSE 250 index.
874, Eonju-ro Gangnam-gu Seoul
Seoul; Seoul; Map
Postal Code: 135811
Full name: Pharmicell Co.,Ltd.
Previous name(s): FCB TWELVE CO.,LTD. (2011)
Legal Form: Public Limited Company
Operational Status: Operational
Incorporation Date: 20-Aug-68
Pharmicell Co.,Ltd. is engaged in manufacturing biopharmaceutical medicines used in curing diseases including cancer, brain, heart diseases and nervous system disorder. The company operates in four business divisions: Stem Cell area is engaged in manufacturing cell therapeutics and stem cell therapeutics ; Bio-based area is engaged in conducting stem cell research; Chemical area is engaged in manufacturing nucleosides, mPEGs, flame retardants, intermediates including TPC, BPDO, IDB-BPD, CarbapenemMore
EMIS Benchmark Score
|Net sales revenue|
|Total operating revenue|
|Operating profit (EBIT)|
|Net Profit (Loss) for the Period|
|Operating Profit (EBIT) Margin|
|Return on Sales (ROS)|
|Return on Equity (ROE)|
|Debt to Equity|
|Company Tear Sheet|
|NAICS Industry Classification||✓||✕|
|Share Price information||✓||✕|
|Subsidiaries and Affiliates||✓||✕|
|Key Financial Highlights||✓||✕|
|Financial Performance Charts||✓||✕|
|Latest M&A and ECM Deals||✓||✕|
|EMIS Credit Analytics|
|EMIS Benchmark Score||✓||✕|
- or -
EMIS company profiles are part of a larger information service that combines company, industry and country data and analysis for over 120 emerging markets on a unique information platform.
If you need broad and deep coverage of one or many countries, you may be interested in subscribing. Request a demonstration of our full service and one of our account managers will be in touch.